Boston, MA 02/07/2013 (wallstreetpr) – Shares of Celsion Corporation (NASDAQ:CLSN) increased by 8.82 percent to close at $1.11 on Monday. The shares recorded an intraday high of $1.14 per share and an intraday low of $1.03 per share during the day. During the last trading session, shares of Celsion Corporation (NASDAQ:CLSN) ranged between a 52-week high of $9.44 and a 52-week low of $0.75 per share.
Celsion Corporation (NASDAQ:CLSN) was trading on Monday at very high volumes, namely at 2.38 million shares, while the average level of trading in the company is 8.52 million shares per day. With 57.10 million shares outstanding in the market, Celsion Corporation (NASDAQ:CLSN) currently has a market cap of $63.38 million and an institutional ownership of 22 percent of total share capital.
Celsion Corporation (NASDAQ:CLSN) is a biopharmaceutical company with a primary focus on the development, production and commercialization of treatment therapies for applications in hard- to-treat forms of cancer. The principal product candidate of the company is ThermoDox, which is being developed as a liposomal encapsulation of the doxorubicin complex. The company is currently performing clinical trials in different phases, with the purpose of testing ThermoDox in the treatment of a wide range of cancers.
As of December 31, 2011, Celsion Corporation (NASDAQ:CLSN) was evaluating the results of Phase III clinical trials of ThermoDox for the treatment of primary liver cancer, Phase II clinical trials for the treatment of recurring chest wall breast cancer and Phase II clinical trials for the treatment of colorectal liver metastasis. The principal product candidate of the company is primarily developed on the application of localized heat at mild temperatures of hyperthermia, which would thereby enable the delivery of doxorubicin in higher doses and exactly at the targeted points of the cancer tumor, so as to get deposited on and around the target point.
